|
1
|
Krook JE, Moertel CG, Gunderson LL, Wieand
HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard
JA, et al: Effective surgical adjuvant therapy for high-risk rectal
carcinoma. N Engl J Med. 324:709–715. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seiwert TY, Salama JK and Vokes EE: The
concurrent chemoradiation paradigm - general principles. Nat Clin
Pract Oncol. 4:86–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siemann DW, Bibby MC, Dark GG, Dicker AP,
Eskens FA, Horsman MR, Marmé D and Lorusso PM: Differentiation and
definition of vascular-targeted therapies. Clin Cancer Res.
11:416–420. 2005.PubMed/NCBI
|
|
4
|
Jubb AM, Pham TQ, Hanby AM, Frantz GD,
Peale FV, Wu TD, Koeppen HW and Hillan KJ: Expression of vascular
endothelial growth factor, hypoxia inducible factor 1α, and
carbonic anhydrase IX in human tumours. J Clin Pathol. 57:504–512.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fong TA, Shawver LK, Sun L, Tang C, App H,
Powell TJ, Kim YH, Schreck R, Wang X, Risau W, et al: SU5416 is a
potent and selective inhibitor of the vascular endothelial growth
factor receptor (Flk-1/KDR) that inhibits tyrosine kinase
catalysis, tumor vascularization, and growth of multiple tumor
types. Cancer Res. 59:99–106. 1999.PubMed/NCBI
|
|
6
|
Huber PE, Bischof M, Jenne J, Heiland S,
Peschke P, Saffrich R, Gröne HJ, Debus J, Lipson KE and Abdollahi
A: Trimodal cancer treatment: Beneficial effects of combined
antiangiogenesis, radiation, and chemotherapy. Cancer Res.
65:3643–3655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bischof M, Abdollahi A, Gong P, Stoffregen
C, Lipson KE, Debus JU, Weber KJ and Huber PE: Triple combination
of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition
(SU5416) in human endothelial and tumor cells. Int J Radiat Oncol
Biol Phys. 60:1220–1232. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krystal GW, Honsawek S, Kiewlich D, Liang
C, Vasile S, Sun L, McMahon G and Lipson KE: Indolinone tyrosine
kinase inhibitors block Kit activation and growth of small cell
lung cancer cells. Cancer Res. 61:3660–3668. 2001.PubMed/NCBI
|
|
9
|
Lu B, Geng L, Musiek A, Tan J, Cao C,
Donnelly E, McMahon G, Choy H and Hallahan DE: Broad spectrum
receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation
via targeting survival pathway of vascular endothelium. Int J
Radiat Oncol Biol Phys. 58:844–850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kharbanda S, Saleem A, Shafman T, Emoto Y,
Taneja N, Rubin E, Weichselbaum R, Woodgett J, Avruch J, Kyriakis
J, et al: Ionizing radiation stimulates a Grb2-mediated association
of the stress-activated protein kinase with phosphatidylinositol
3-kinase. J Biol Chem. 270:18871–18874. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (Review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
12
|
Begg AC, Stewart FA and Vens C: Strategies
to improve radiotherapy with targeted drugs. Nat Rev Cancer.
11:239–253. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cherrington JM, Strawn LM and Shawver LK:
New paradigms for the treatment of cancer: The role of
anti-angiogenesis agents. Adv Cancer Res. 79:1–38. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wachsberger P, Burd R and Dicker AP: Tumor
response to ionizing radiation combined with antiangiogenesis or
vascular targeting agents: Exploring mechanisms of interaction.
Clin Cancer Res. 9:1957–1971. 2003.PubMed/NCBI
|
|
15
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trials on anti-VEGF therapy for
cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stadler WM, Heimann R, Karczmar GS,
Gajewski T, Kindler H, MacEaneny P, Zamora M, Medved M and Vokes E:
Clinical evaluation of tumor angiogenesis markers in metastatic
cancer. Proc Am Soc Clin Oncol. 20:3822001.
|
|
17
|
Timke C, Zieher H, Roth A, Hauser K,
Lipson KE, Weber KJ, Debus J, Abdollahi A and Huber PE: Combination
of vascular endothelial growth factor receptor/platelet-derived
growth factor receptor inhibition markedly improves radiation tumor
therapy. Clin Cancer Res. 14:2210–2219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bernier J, Hall EJ and Giaccia A:
Radiation oncology: A century of achievements. Nat Rev Cancer.
4:737–747. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brooks PC: Cell adhesion molecules in
angiogenesis. Cancer Metastasis Rev. 15:187–194. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Basset P, Okada A, Chenard MP, Kannan R,
Stoll I, Anglard P, Bellocq JP and Rio MC: Matrix
metalloproteinases as stromal effectors of human carcinoma
progression: Therapeutic implications. Matrix Biol. 15:535–541.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnsen M, Lund LR, Rømer J, Almholt K and
Danø K: Cancer invasion and tissue remodeling: Common themes in
proteolytic matrix degradation. Curr Opin Cell Biol. 10:667–671.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
